Chardan Capital Markets analyst Keay Nakae raised the price target on BioSig Technologies (OTC: BSGM) to $12.50 (from $5.00) while maintaining a Buy rating ahead of NASDAQ uplisting.
Nakae commented, “The Company announced that its shares of common stock have been approved for trading on the Nasdaq Capital Market. The shares will commence trading on Nasdaq CM on Friday, September 21. Last week on Sept 11, the Company effected a 1:2.5 reverse split of its stock as a final step to facilitate the uplist from the OTCQB. Last month the Company obtained FDA 510(k) clearance of its first product, PURE EP. The PURE EP System is designed to assist electrophysiologists in making real-time clinical decisions by providing better information than can be obtained from common equipment currently used in EP labs.”
